

I. AMENDMENTS

AMENDMENTS TO THE CLAIMS

Cancel claims 3 and 4 without prejudice to renewal.

Please enter the amendments to claims 1, 13, 16, and 17, as shown below.

1. (Currently amended) A recombinant Modified Vaccinia Vaccine Ankara (MVA) virus comprising at least one nucleic acid coding for a *Plasmodium falciparum* merozoite surface protein-1 (MSP-1) protein or a fragment or mutein thereof, wherein the fragment of MSP-1 is selected from the fragments p83, p30, p38, p33, p19, and p42, or a combination thereof, and wherein the mutein comprises an amino acid sequence that differs from the MSP-1 amino acid sequence by addition, deletion, insertion, inversion, and/or substitution of one or more amino acids.

2. (Previously presented) The recombinant MVA virus according to Claim 1, wherein the MSP-1 protein is the MSP-1 protein of the isolate 3D7 or the MSP-1 protein of the FCB1 strain.

3.-4. (Canceled)

5. (Previously presented) The recombinant MVA virus according to Claim 1, wherein the nucleic acid coding for MSP-1 is reduced in its adenine and thymine (AT) content compared to the wild type sequence.

6. (Previously presented) The recombinant MVA virus according to Claim 1, wherein the nucleic acid coding for MSP-1 is under the control of a promoter.

7. (Previously presented) The recombinant MVA virus according to Claim 1, wherein the nucleic acid at the 5' end is fused with a nucleotide sequence coding for a signal peptide sequence.

8. (Previously presented) The recombinant MVA virus according to Claim 7, wherein the signal peptide sequence controls the secretion of the gene product.

9. (Previously presented) The recombinant MVA virus according to Claim 7, wherein the signal peptide sequence controls the localisation of the gene product to the membrane.
10. (Previously presented) The recombinant MVA virus according to Claim 7, wherein the signal sequence controls the glycosylphosphatidylinositol anchoring of the gene product.
11. (Previously presented) A method of production of a recombinant Modified Vaccinia Vaccine Ankara (MVA) virus, wherein the method comprises the steps:
- a) transfecting a eukaryotic host cell with a transfer vector, wherein
 - i) the transfer vector comprises a nucleic acid encoding a *Plasmodium falciparum* merozoite surface protein-1 (MSP-1) protein, or a fragment or a mutein thereof, wherein the mutein differs by the addition, deletion, insertion, inversion and / or substitution of one or more amino acids from the MSP-1 sequence; and optionally also comprises a selection marker;
 - ii) the nucleic acid according to i) is flanked by MVA sequences 5' and / or 3', wherein the sequences are suitable for the homologous recombination in the host cell;
 - b) infection with a virus based on MVA, preferably MVA;
 - c) cultivation of the host cell under conditions suitable for homologous recombination; and
 - d) isolation of the recombinant virus based on MVA.
12. (Previously presented) The method according to Claim 11, wherein the virus is isolated from the culture supernatant or from the cultivated host cells.
13. (Currently amended) A vaccine comprising:
- a) the recombinant virus according to one of Claims 1, 2, and 5-9 ~~the Claims 1 to 9~~ ; and
 - b) a pharmacologically compatible carrier.
14. (Previously presented) The vaccine according to Claim 13, further comprising: c) MSP-1, a fragment or a mutein thereof and / or a nucleic acid coding for MSP-1, or a fragment or mutein thereof.
15. (Previously presented) The vaccine according to Claim 14, wherein the constituents a) and c) can be administered simultaneously, sequentially or separately.

16. (Currently amended) A method for the prophylaxis and / or therapy of malaria, the method comprising administering the recombinant virus of any one of Claims 1, 2, and 5-9 ~~claims 1 to 9~~.

17. (Currently amended) A method for the prophylaxis and / or therapy of malaria, the method comprising administering: i) a recombinant virus according to one of claims 1, 2, and 5-8 ~~1 to 8~~; and ii) MSP-1, a fragment or a mutein thereof and / or a nucleic acid coding for MSP-1, or a fragment or mutein thereof, wherein the fragment of MSP-1 is selected from the fragments p83, p30, p38, p33, p19, and p42, or a combination thereof, and wherein the mutein comprises an amino acid sequence that differs from the MSP-1 amino acid sequence by addition, deletion, insertion, inversion, and/or substitution of one or more amino acids.